Letchumanan Michelle, Coyte Peter C, Loutfy Mona
Women's College Research Institute, Women's College Hospital, Toronto, ON, Canada.
Antivir Ther. 2015;20(6):613-21. doi: 10.3851/IMP2956. Epub 2015 Apr 7.
To conduct an economic evaluation of the three commonly used interventions that reduce sexual HIV transmission when an HIV-negative female aims to conceive with an HIV-positive male on combination antiretroviral therapy (condomless sex restricted to timed ovulation [CS], sperm washing with intrauterine insemination [SW] and condomless sex restricted to timed ovulation with pre-exposure prophylaxis [CS-PrEP]). As SW and CS-PrEP are only privately available for pregnancy planning for this population in Canada, this study was conducted to inform policy decisions concerning potential public health insurance coverage, as well as to inform fertility counselling in settings with adequate combination antiretroviral therapy access globally.
We developed a cohort Markov model with a lifetime horizon and used the perspective of Ontario's Ministry of Health (MOH). Input parameters were drawn from literature, the MOH's Schedule of Benefits and a time trade-off questionnaire designed for this study. Outcome measures included quality-adjusted life-years and incremental cost-effectiveness. Costs and benefits were discounted at annual rates of 3%. Costs were reported in Canadian 2013 dollars and an exchange rate of 1 USD to 1.066 CND was applied where necessary. Sensitivity analysis assessed the uncertainty of model parameters.
The base case analysis found that CS-PrEP and SW were each more costly and less effective at conception than CS. The results were robust in the sensitivity analysis and suggest that CS is the dominant conception strategy in this population.
Neither CS-PrEP nor SW represent better value for money relative to CS as a conception option for HIV-discordant couples with positive male partners. Based on these findings, CS-PrEP and SW cannot be recommended for public-funding in developed countries.
对三种常用干预措施进行经济评估,这三种措施用于在未感染艾滋病毒的女性打算与接受联合抗逆转录病毒治疗的艾滋病毒阳性男性受孕时降低艾滋病毒的性传播风险(无保护性行为仅限于排卵期[CS]、宫内人工授精前进行精子清洗[SW]以及无保护性行为仅限于排卵期并进行暴露前预防[CS-PrEP])。由于在加拿大,SW和CS-PrEP仅可通过私人途径用于该人群的妊娠计划,开展本研究旨在为有关潜在公共医疗保险覆盖范围的政策决策提供信息,并为全球范围内能够获得充分联合抗逆转录病毒治疗的地区提供生育咨询服务。
我们构建了一个具有终生时间范围的队列马尔可夫模型,并采用安大略省卫生部(MOH)的视角。输入参数取自文献、MOH的福利清单以及为本研究设计的时间权衡问卷。结果指标包括质量调整生命年和增量成本效益。成本和效益按3%的年利率进行贴现。成本以2013年加拿大元报告,必要时采用1美元兑换1.066加元的汇率。敏感性分析评估了模型参数的不确定性。
基础案例分析发现,CS-PrEP和SW在受孕方面的成本均高于CS,且效果不如CS。敏感性分析结果稳健,表明CS是该人群中的主要受孕策略。
对于男性伴侣为阳性的艾滋病毒不一致夫妇而言,作为受孕选择,CS-PrEP和SW相对于CS而言,性价比均不高。基于这些发现,在发达国家不建议为CS-PrEP和SW提供公共资金支持。